OBJECTIVE: To summarize the literature on the risk of AEFI recurrence. DATA SOURCES:
PubMed, Embase, and Cochrane library. STUDY SELECTION: We included articles in …

Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Background Pertussis vaccination during pregnancy can prevent 91% of infant infections. In
2015, antenatal pertussis vaccination programs were introduced across Australia. Methods …

Immunization with acellular pertussis vaccine (aP) induces higher specific antibody levels
and fewer adverse reactions than does immunization with the whole-cell vaccine (wP) …

Objectives The surveillance of vaccine safety is an essential requirement in vaccination
programmes. Computerized immunization registries such as the Vaccination Information …

Objectives To estimate the risk of recurrence of adverse events following immunization
(AEFIs) upon revaccination and to determine among patients with suspected vaccine allergy …

Background: For patients who have experienced adverse events following immunization
(AEFI) or who have specific medical conditions, there is limited evidence regarding the best …

Objective Prior experience of an adverse event following immunisation is a known barrier to
vaccination. Limited Australian data evaluating adverse event recurrence among children …

Background: While adverse events following immunization (AEFI) are frequent, there are
limited data on the safety of reimmunizing patients who had a prior AEFI. Our objective was …

Vaccines have been extremely successful in reducing morbidity and mortality from vaccine‐
preventable diseases. However, given that few vaccine‐preventable diseases currently are …